on Pentixapharm Holding AG (ETR:PTP)
Pentixapharm to Release Financial Results for Q3 and Nine Months of 2025
Pentixapharm Holding AG is set to announce its financial results for the third quarter and the first nine months of 2025 on November 12. The biotech company, which operates at an advanced clinical stage with a focus on radiopharmaceuticals, will also provide a business update on the same day.
The management will host a conference call and webcast at 3 p.m. CET to discuss the quarterly results. Participants can access the webcast and presentation through the company’s website.
Pentixapharm, based in Berlin, develops novel radiopharmaceuticals, particularly in oncology. Their pipeline includes CXCR4-targeted programs and an innovative platform targeting CD24 in various cancers.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Pentixapharm Holding AG news